Alimta (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Alimta (pemetrexed disodium) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 35
6.4 SWOT Analysis 35
6.5 Forecast 36
7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 41
7.3 Methodology 44
7.4 Forecasting Methodology 44
7.4.1 Number of NSCLC Patients Currently Seeking Treatment 44
7.4.2 Percent Drug-treated Patients 45
7.4.3 General Pricing Assumptions 45
7.4.4 Individual Drug Assumptions 48
7.4.5 Generic Erosion 49
7.5 Physicians and Specialists Included in This Study 49
7.6 Survey of Prescribing Physicians 50
7.7 About the Authors 51
7.7.1 Author 51
7.7.2 Epidemiologist 51
7.7.3 Global Head of Healthcare 52
7.8 About GlobalData 53
7.9 Disclaimer 53